In yesterday’s Wall Street session, PaxMedica Inc (NASDAQ:PXMD) shares traded at $1.07, up 4.90% from the previous session.
PXMD stock price is now -71.43% away from the 50-day moving average and -94.03% away from the 200-day moving average. The market capitalization of the company currently stands at $1.08M.
In other news, Rome Zachary, Director sold 16,301 shares of the company’s stock on Oct 27. The stock was sold for $3,012 at an average price of $0.18. Upon completion of the transaction, the Director now directly owns 277,390 shares in the company, valued at $0.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 27, 10% Owner Derby Michael sold 9,175 shares of the business’s stock. A total of $1,740 was realized by selling the stock at an average price of $0.19. This leaves the insider owning 439,171 shares of the company worth $0.47 million. A total of 67.65% of the company’s stock is owned by insiders.
On Friday morning PaxMedica Inc (NASDAQ: PXMD) stock kicked off with the opening price of $1.1200. During the past 12 months, PaxMedica Inc has had a low of $0.80 and a high of $69.19. The fifty day moving average price for PXMD is $3.6645 and a two-hundred day moving average price translates $17.6602 for the stock.
The latest earnings results from PaxMedica Inc (NASDAQ: PXMD) was released for Sep, 2023. The company reported revenue of $4.37 million for the quarter, compared to $2.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 61.97 percent.
PaxMedica Inc(PXMD) Company Profile
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company’s lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
